CHEK2 and breast carcinoma: The compound also inhibited the expression of ATR, resulted in the phosphorylation of Chk1 at Ser317, Chk2 at Thr68, wild-type p53 at Ser15, and H2AX at Ser139 in breast cancer cells (Figure 4D).